ANI Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of Directors: Thomas J. Haughey

ANI Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Thomas Haughey”): 14,732,894 for, 159,765 against, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) each of the seven (7) director nominees were elected, (ii) the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, (iii) the compensation of the Company's named executiv…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 7,073,922 for, 3,971 against, 1,630 abstained.

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

Description as filed by funds: Election of Directors: Antonio R. Pera

ANI Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Antonio R. Pera”): 14,542,012 for, 350,649 against, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) each of the seven (7) director nominees were elected, (ii) the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, (iii) the compensation of the Company's named executiv…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 7,077,891 for, 2 against, 1,630 abstained.

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

Description as filed by funds: Election of Directors: Jeanne A. Thoma

ANI Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jeanne A. Thoma”): 14,565,758 for, 327,393 against, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) each of the seven (7) director nominees were elected, (ii) the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, (iii) the compensation of the Company's named executiv…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 6,937,891 for, 2 against, 1,630 abstained.

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

Description as filed by funds: Election of Directors: Matthew J. Leonard, R.Ph.

ANI Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Matthew J. Leonard, R.Ph.”): 14,743,471 for, 149,095 against, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) each of the seven (7) director nominees were elected, (ii) the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, (iii) the compensation of the Company's named executiv…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 7,076,374 for, 1,519 against, 1,630 abstained.

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

Description as filed by funds: Election of Directors: Muthusamy Shanmugam

ANI Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Muthusamy Shanmugam”): 14,849,624 for, 42,253 against, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) each of the seven (7) director nominees were elected, (ii) the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, (iii) the compensation of the Company's named executiv…”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 7,077,893 for, 1,630 abstained.

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

Description as filed by funds: Election of Directors: Nikhil Lalwani

ANI Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Nikhil Lalwani”): 14,873,796 for, 15,198 against, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) each of the seven (7) director nominees were elected, (ii) the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, (iii) the compensation of the Company's named executiv…”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 7,077,893 for, 1,630 abstained.

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

Description as filed by funds: Election of Directors: Renee P. Tannenbaum, Pharm.D.

ANI Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Renee P. Tannenbaum, Pharm.D.”): 14,063,620 for, 829,566 against, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) each of the seven (7) director nominees were elected, (ii) the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, (iii) the compensation of the Company's named executiv…”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 6,859,432 for, 268,461 against, 1,630 abstained.

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

Description as filed by funds: To approve the Amended and Restated 2022 Stock Incentive Plan.

ANI Pharmaceuticals, Inc.’s own tally for this item (“5. Approval of the Amended 2022 Stock Plan The vote with respect to the approval of the Amended 2022 Stock Plan”): 13,806,050 for, 1,080,387 against, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 96 asset managers below reported 6,561,513 for, 376,450 against, 1,630 abstained.

Showing the 25 largest of 96 asset managers. See all 96 in the interactive database.

Description as filed by funds: To approve the compensation of the Company's named executive officers, on a non-binding, advisory basis.

ANI Pharmaceuticals, Inc.’s own tally for this item (“3. Approval of the Say-on-Pay Proposal The vote with respect to the approval of the compensation of the Company's named executive officers, on an advisory basis”): 13,819,988 for, 1,058,460 against, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 95 managers: 6,735,906 for, 341,938 against, 1,630 abstained, 2 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 254 managers: 8,749,800 for, 886,910 against, 26,296 not voted, 16,083 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To approve the frequency of future advisory votes to approve the compensation of the Company's named executive officers, on a non- binding, advisory basis.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 75 managers: 47,902 for, 1,630 abstained, 2 not voted, 4,954,242 1 year, 142,815 3 year, 64,751 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 170 managers: 22,809 for, 3,000 not voted, 6,922,159 1 year, 74,455 3 year, 1 2 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To approve the frequency of future advisory votes to approve the compensation of the Company's named executive officers, on a non-binding basis.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 20 managers: 1,837,361 1 year, 7,218 3 year.

Institutional-manager reports, all 74 managers: 2,566,685 1 year, 11,131 3 year, 1 2 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.

ANI Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the Appointment of Independent Registered Public Accounting Firm The vote with respect to the ratification of the appointment of Ernst & Young LLP as the Company's independent registered public account”): 16,874,103 for, 7,333 against, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 6,937,893 for, 1,630 abstained.

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.